FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134186455> ?p ?o ?g. }

• W2134186455 endingPage "273" @default.
• W2134186455 startingPage "267" @default.
• W2134186455 abstract "Abstract Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify maximum-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (PD) activity. Experimental Design: AT9283 was administered as a 72-hour continuous intravenous infusion every 3 weeks. A rolling-six design, explored six dose levels (7, 9, 11.5, 14.5, 18.5, and 23 mg/m2/d). Pharmacokinetic and PD assessments, included inhibition of phospho-histone 3 (pHH3) in paired skin punch biopsies. Results: Thirty-three patients were evaluable for toxicity. There were six dose-limiting toxicities and the MTD was 18.5 mg/m2/d. Most common drug-related toxicities were hematologic (neutropenia, anemia, and thrombocytopenia in 36.4%, 18.2%, and 21.2% of patients), which were grade ≥3 in 30.3%, 6.1%, and 3% of patients. Nonhematologic toxicities included fatigue, infections, febrile neutropenia and ALT elevation. One patient with central nervous system–primitive neuroectodermal tumor (CNS-PNET) achieved a partial response after 16 cycles and 3 cases were stable for four or more cycles. Plasma concentrations were comparable with those in adults at the same dose level, clearance was similar although half-life was shorter (4.9 ± 1.5 hours, compared with 8.4 ± 3.7 hours in adults). Inhibition of Aurora kinase B was shown by reduction in pHH3 in 17 of 18 patients treated at ≥11.5 mg/m2/d. Conclusion: AT9283 was well tolerated in children and adolescents with solid tumors with manageable hematologic toxicity. Target inhibition was demonstrated. Disease stabilization was documented in intracranial and extracranial pediatric solid tumors and a phase II dose determined. Clin Cancer Res; 21(2); 267–73. ©2014 AACR." @default.
• W2134186455 created "2016-06-24" @default.
• W2134186455 creator A5011342082 @default.
• W2134186455 creator A5012124144 @default.
• W2134186455 creator A5013139347 @default.
• W2134186455 creator A5013529173 @default.
• W2134186455 creator A5023191275 @default.
• W2134186455 creator A5027866282 @default.
• W2134186455 creator A5031453300 @default.
• W2134186455 creator A5036070143 @default.
• W2134186455 creator A5047068506 @default.
• W2134186455 creator A5047171127 @default.
• W2134186455 creator A5050224107 @default.
• W2134186455 creator A5052706160 @default.
• W2134186455 creator A5057241786 @default.
• W2134186455 creator A5057446858 @default.
• W2134186455 creator A5067330530 @default.
• W2134186455 creator A5074649319 @default.
• W2134186455 creator A5085457887 @default.
• W2134186455 creator A5085820190 @default.
• W2134186455 date "2015-01-14" @default.
• W2134186455 modified "2023-10-02" @default.
• W2134186455 title "A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study" @default.
• W2134186455 cites W1601758486 @default.
• W2134186455 cites W2001440545 @default.
• W2134186455 cites W2020481917 @default.
• W2134186455 cites W2038644375 @default.
• W2134186455 cites W2072015866 @default.
• W2134186455 cites W2096398040 @default.
• W2134186455 cites W2097010776 @default.
• W2134186455 cites W2103146352 @default.
• W2134186455 cites W2104438003 @default.
• W2134186455 cites W2105913640 @default.
• W2134186455 cites W2108541596 @default.
• W2134186455 cites W2116003832 @default.
• W2134186455 cites W2131815304 @default.
• W2134186455 cites W2139248078 @default.
• W2134186455 cites W2143265289 @default.
• W2134186455 cites W2147066734 @default.
• W2134186455 cites W2151962695 @default.
• W2134186455 cites W2171285924 @default.
• W2134186455 cites W3081481998 @default.
• W2134186455 doi "https://doi.org/10.1158/1078-0432.ccr-14-1592" @default.
• W2134186455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25370467" @default.
• W2134186455 hasPublicationYear "2015" @default.
• W2134186455 type Work @default.
• W2134186455 sameAs 2134186455 @default.
• W2134186455 citedByCount "40" @default.
• W2134186455 countsByYear W21341864552015 @default.
• W2134186455 countsByYear W21341864552016 @default.
• W2134186455 countsByYear W21341864552017 @default.
• W2134186455 countsByYear W21341864552018 @default.
• W2134186455 countsByYear W21341864552019 @default.
• W2134186455 countsByYear W21341864552020 @default.
• W2134186455 countsByYear W21341864552021 @default.
• W2134186455 countsByYear W21341864552022 @default.
• W2134186455 countsByYear W21341864552023 @default.
• W2134186455 crossrefType "journal-article" @default.
• W2134186455 hasAuthorship W2134186455A5011342082 @default.
• W2134186455 hasAuthorship W2134186455A5012124144 @default.
• W2134186455 hasAuthorship W2134186455A5013139347 @default.
• W2134186455 hasAuthorship W2134186455A5013529173 @default.
• W2134186455 hasAuthorship W2134186455A5023191275 @default.
• W2134186455 hasAuthorship W2134186455A5027866282 @default.
• W2134186455 hasAuthorship W2134186455A5031453300 @default.
• W2134186455 hasAuthorship W2134186455A5036070143 @default.
• W2134186455 hasAuthorship W2134186455A5047068506 @default.
• W2134186455 hasAuthorship W2134186455A5047171127 @default.
• W2134186455 hasAuthorship W2134186455A5050224107 @default.
• W2134186455 hasAuthorship W2134186455A5052706160 @default.
• W2134186455 hasAuthorship W2134186455A5057241786 @default.
• W2134186455 hasAuthorship W2134186455A5057446858 @default.
• W2134186455 hasAuthorship W2134186455A5067330530 @default.
• W2134186455 hasAuthorship W2134186455A5074649319 @default.
• W2134186455 hasAuthorship W2134186455A5085457887 @default.
• W2134186455 hasAuthorship W2134186455A5085820190 @default.
• W2134186455 hasConcept C111113717 @default.
• W2134186455 hasConcept C112705442 @default.
• W2134186455 hasConcept C121608353 @default.
• W2134186455 hasConcept C126322002 @default.
• W2134186455 hasConcept C143998085 @default.
• W2134186455 hasConcept C2777063308 @default.
• W2134186455 hasConcept C2778248108 @default.
• W2134186455 hasConcept C2778850193 @default.
• W2134186455 hasConcept C2779984678 @default.
• W2134186455 hasConcept C29730261 @default.
• W2134186455 hasConcept C31760486 @default.
• W2134186455 hasConcept C535046627 @default.
• W2134186455 hasConcept C71924100 @default.
• W2134186455 hasConcept C90924648 @default.
• W2134186455 hasConcept C98274493 @default.
• W2134186455 hasConceptScore W2134186455C111113717 @default.
• W2134186455 hasConceptScore W2134186455C112705442 @default.
• W2134186455 hasConceptScore W2134186455C121608353 @default.
• W2134186455 hasConceptScore W2134186455C126322002 @default.
• W2134186455 hasConceptScore W2134186455C143998085 @default.
• W2134186455 hasConceptScore W2134186455C2777063308 @default.
• W2134186455 hasConceptScore W2134186455C2778248108 @default.

• next